Literature DB >> 11396201

Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia.

L M Lee1, C C Pan, C J Cheng, C W Chi, T Y Liu.   

Abstract

Elevated expression of cyclo-oxygenase (COX)-2 has been found in several human cancers, including prostate adenocarcinoma. To evaluate the potential prognostic role of COX-2 in prostate cancer, we assessed the expression of COX-2 in benign prostatic hyperplasia (BPH) and prostate cancer samples employing immunohistochemistry. COX-2 was over-expressed in 15 out of 18 (83%) prostate cancer samples whereas it was detected in only 22% (4 of 18) paired benign tissues. The intensity of immunostaining correlated with the tumor grading. In addition, COX-2 was expressed in 7 of the 22 (32%) BPH samples examined. The significance a COX-2 expression in the BPH samples is not known at present. This data suggest that COX-2 is over-expressed in prostate cancer and COX-2 inhibitors may be useful in combination chemotherapy or chemoprevention for prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11396201

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  30 in total

Review 1.  COX-2 and cancer: a new approach to an old problem.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 2.  Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review.

Authors:  Onder Onguru; Mary B Casey; Sabine Kajita; Nobuki Nakamura; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

3.  Roles of Eicosanoids in Prostate Cancer.

Authors:  Kasem Nithipatikom; William B Campbell
Journal:  Future Lipidol       Date:  2008-08-01

Review 4.  The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis.

Authors:  Prasanna Ekambaram; Wanyu Lambiv; Rosanna Cazzolli; Anthony W Ashton; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

5.  Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.

Authors:  C-J Ko; S-W Lan; Y-C Lu; T-S Cheng; P-F Lai; C-H Tsai; T-W Hsu; H-Y Lin; H-Y Shyu; S-R Wu; H-H Lin; P-W Hsiao; C-H Chen; H-P Huang; M-S Lee
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

6.  Nutrigenomics: a case for the common soil between cardiovascular disease and cancer.

Authors:  Licia Iacoviello; Iolanda Santimone; Maria Carmela Latella; Giovanni de Gaetano; Maria Benedetta Donati
Journal:  Genes Nutr       Date:  2008-04       Impact factor: 5.523

7.  Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer.

Authors:  Manish I Patel; Jaskirat Singh; Marzieh Niknami; Caroline Kurek; Mu Yao; Sasa Lu; Fiona Maclean; Nicholas J C King; Michael H Gelb; Kieran F Scott; Pamela J Russell; John Boulas; Qihan Dong
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

8.  Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine.

Authors:  Rita Ghosh; Gretchen E Garcia; Katherine Crosby; Hiroyasu Inoue; Ian M Thompson; Dean A Troyer; Addanki P Kumar
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

9.  Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion.

Authors:  Kasem Nithipatikom; Marilyn A Isbell; Paul F Lindholm; Andre Kajdacsy-Balla; Sushma Kaul; William B Campell
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

10.  COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.

Authors:  Li-Yan Khor; Kyounghwa Bae; Alan Pollack; M Elizabeth H Hammond; David J Grignon; Varagur M Venkatesan; Seth A Rosenthal; Mark A Ritter; Howard M Sandler; Gerald E Hanks; William U Shipley; Adam P Dicker
Journal:  Lancet Oncol       Date:  2007-09-18       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.